Paradigm Therapeutics Named Prix Galien Finalist
The Mount Pleasant biotech firm earned a finalist spot for the 2026 Prix Galien USA Best Start-Up Award.
Live Poll
Should the public place higher priority on supporting new companies developing treatments for rare diseases?